Open an account

ArriVent BioPharma

AVBP · NASDAQ

$18.85+$0.91 (+5.07%)TodayMarket closed ·
Prev close $17.94

About AVBP

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.

Employees
77
Headquarters
Newtown Square, Pennsylvania
Listed
Jan 26, 2024
Sector
Health Care
Industry
Biotechnology
Website
arrivent.com

AVBP key statistics

Market cap
884.58M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.15M
Volume
817.87K
Open price
$17.94
High today
$18.98
Low today
$17.57
52 Week high
$35.83
52 Week low
$11.36

ArriVent BioPharma (AVBP) at a glance

ArriVent BioPharma (AVBP) last traded at $18.85, with a market cap of 884.58M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.57 and $18.98. The current price is 7.3% above the day's low and 0.7% below its high.

Volume so far is 817.87K shares, below the average of 2.15M shares a day.

Over the past year ArriVent BioPharma has ranged from $11.36 to $35.83, and now sits 31% of the way up that range.

ArriVent BioPharma met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.05 per share against an estimate of -$1.01.

The average analyst price target is $45.81, 143.0% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $45.81
Low
$40.40
Now
$18.85
High
$52.50

AVBP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 24.3% on average.

  1. Q3 FY24: reported -$0.61 per share against an estimate of -$1.02
  2. Q4 FY24: reported -$0.61 per share against an estimate of -$0.7925
  3. Q1 FY25: reported -$1.90 per share against an estimate of -$0.6773
  4. Q2 FY25: reported -$0.90 per share against an estimate of -$0.7178
  5. Q3 FY25: reported -$0.83 per share against an estimate of -$0.8051
  6. Q4 FY25: reported -$0.78 per share against an estimate of -$0.8643
  7. Q1 FY26: reported -$0.96 per share against an estimate of -$0.9126
  8. Q2 FY26: reported -$1.05 per share against an estimate of -$1.01

AVBP news

  • Press releaseGlobe Newswire

    ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  • Press releasePRNewswire

    ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

  • Press releaseBusiness Wire

    AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

  • Press releasePRNewswire

    ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)

  • Vandana Singh

    ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

  • Avi Kapoor

    Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings

  • Avi Kapoor

    Dow Jumps 200 Points; US Trade Deficit Widens In August

Similar companies

Companies in the same industry as ArriVent BioPharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.